Dyckhoff Gerhard, Warta Rolf, Herold-Mende Christel, Winkler Volker, Plinkert Peter K, Ramroth Heribert
Department of Otorhinolaryngology, Head and Neck Surgery, University of Heidelberg, 69120 Heidelberg, Germany.
Division of Neurosurgical Research, Department of Neurosurgery, University of Heidelberg, 69120 Heidelberg, Germany.
Cancers (Basel). 2021 Jul 8;13(14):3435. doi: 10.3390/cancers13143435.
For advanced laryngeal cancers, after randomized prospective larynx preservation studies, nonsurgical therapy has been applied on a large scale as an alternative to laryngectomy. For T4 laryngeal cancer, poorer survival has been reported after nonsurgical treatment. Is there a need to fear worse survival also in T3 tumors? The outcomes of 121 T3 cancers treated with pCRT, pRT alone, or surgery were evaluated in an observational cohort study in Germany. In a multivariate Cox regression of the T3 subgroup, no survival difference was noted between pCRT and total laryngectomy with risk-adopted adjuvant (chemo)radiotherapy (TL ± a(C)RT) (HR 1.20; 95%-CI: 0.57-2.53; = 0.63). However, survival was significantly worse after pRT alone than after TL ± a(C)RT (HR 4.40; 95%-CI: 1.72-11.28, = 0.002). A literature search shows that in cases of unfavorable prognostic markers (bulky tumors of 6-12 ccm, vocal cord fixation, minimal cartilage infiltration, or N2-3), pCRT instead of pRT is indicated. In cases of pretreatment dysphagia or aspiration requiring a feeding tube or tracheostomy, gross or multiple cartilage infiltration, or tumor volume > 12 ccm, outcomes after pCRT were significantly worse than those after TL. In these cases, and in cases where pCRT is indicated but the patient is not suitable for the addition of chemotherapy, upfront total laryngectomy with stage-appropriate aRT is recommended even in T3 laryngeal cancers.
对于晚期喉癌,在随机前瞻性喉保留研究之后,非手术治疗已被大规模应用,作为喉切除术的替代方法。对于T4期喉癌,据报道非手术治疗后的生存率较低。T3期肿瘤是否也需要担心生存率更差呢?在德国的一项观察性队列研究中,评估了121例接受同步放化疗(pCRT)、单纯放疗(pRT)或手术治疗的T3期癌症患者的结局。在T3亚组的多变量Cox回归分析中,pCRT与全喉切除术加风险调整辅助(化疗)放疗(TL±a(C)RT)之间未观察到生存差异(风险比[HR] 1.20;95%置信区间[CI]:0.57 - 2.53;P = 0.63)。然而,单纯pRT后的生存率明显低于TL±a(C)RT后的生存率(HR 4.40;95%CI:1.72 - 11.28,P = 0.002)。文献检索表明,在预后不良标志物的情况下(6 - 12立方厘米的巨大肿瘤、声带固定、最小软骨浸润或N2 - 3),应采用pCRT而非pRT。在预处理时有吞咽困难或误吸需要鼻饲管或气管造口术、大体或多处软骨浸润或肿瘤体积>12立方厘米的情况下,pCRT后的结局明显比TL后的结局差。在这些情况下,以及在需要pCRT但患者不适合加用化疗的情况下,即使是T3期喉癌,也建议先行全喉切除术并进行适当分期的辅助放疗。